Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 12:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 121 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Unresectable Stage III or Stage IV Melanoma Clear all
Completed Phase 3 Interventional Results available

A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

NCT01006980
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Vemurafenib, Dacarbazine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
24
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Jun 11, 2026, 12:18 AM EDT
Terminated Phase 2 Interventional

Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma

NCT00082875
View directory record Official record
Conditions
Stage III Melanoma, Stage IV Melanoma
Interventions
cilengitide, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Jun 11, 2026, 12:18 AM EDT
Recruiting Phase 1Phase 2 Interventional

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

NCT05655312
View directory record Official record
Conditions
Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III
Interventions
[203Pb]VMT01, [212Pb]VMT01, Nivolumab
Drug
Lead sponsor
Perspective Therapeutics
Industry
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
13
States / cities
Orange, California • Jacksonville, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jun 11, 2026, 12:18 AM EDT
Completed Phase 3 Interventional Results available

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

NCT01597908
View directory record Official record
Conditions
Melanoma
Interventions
Dabrafenib, Vemurafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Gilbert, Arizona • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Jun 11, 2026, 12:18 AM EDT
Terminated Phase 2 Interventional Results available

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

NCT01586195
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Vemurafenib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
16 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
15
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Jun 11, 2026, 12:18 AM EDT
Active, not recruiting Phase 1 Interventional

Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

NCT03021460
View directory record Official record
Conditions
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jun 11, 2026, 12:18 AM EDT
Terminated Phase 2 Interventional

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

NCT01605162
View directory record Official record
Conditions
Wild Type BRAF Stage IV Melanoma, Unresectable Stage III Melanoma
Interventions
TMZ, E7016
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Jun 11, 2026, 12:18 AM EDT
Terminated Phase 2 Interventional

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

NCT04375527
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8, Locally Advanced Cutaneous Melanoma, Metastatic Cutaneous Melanoma, Pathologic Stage III Cutaneous Melanoma AJCC V8, Pathologic Stage IIIA Cutaneous Melanoma AJCC V8, Pathologic Stage IIIB Cutaneous Melanoma AJCC V8, Pathologic Stage IIIC Cutaneous Melanoma AJCC V8, Pathologic Stage IIID Cutaneous Melanoma AJCC V8, Pathologic Stage IV Cutaneous Melanoma AJCC V8, Unresectable Cutaneous Melanoma
Interventions
Binimetinib, Nivolumab, Questionnaire Administration
Drug · Biological · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Jun 11, 2026, 12:18 AM EDT
Active, not recruiting Phase 2 Interventional

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

NCT04940299
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Renal Pelvis Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Malignant Solid Neoplasm, Metastatic Bladder Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Carcinoma, Metastatic Urethral Urothelial Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Lung Cancer AJCC v6, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Ipilimumab, Nivolumab, Tocilizumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jun 11, 2026, 12:18 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma

NCT02452281
View directory record Official record
Conditions
Melanoma
Interventions
ipilimumab, HSPPC-96
Drug
Lead sponsor
Rabih Said
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2016 · Synced Jun 11, 2026, 12:18 AM EDT
Completed Phase 1 Interventional

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

NCT02141542
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Tremelimumab, MEDI3617
Drug
Lead sponsor
F. Stephen Hodi, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2023 · Synced Jun 11, 2026, 12:18 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

NCT01433991
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Golvatinib, Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Jun 11, 2026, 12:18 AM EDT
Completed Phase 1 Interventional

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

NCT02935790
View directory record Official record
Conditions
Malignant Melanoma
Interventions
ACY-241, nivolumab, ipilimumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Jun 11, 2026, 12:18 AM EDT
Recruiting Phase 2 Interventional

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients

NCT06284590
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV
Interventions
L19IL2, L19TNF, L19IL2/L19TNF, KEYTRUDA®
Drug
Lead sponsor
Philogen S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Jun 11, 2026, 12:18 AM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Jun 11, 2026, 12:18 AM EDT
Terminated Early Phase 1 Interventional

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

NCT00499733
View directory record Official record
Conditions
Cancer
Interventions
cyclophosphamide, Cryoablation
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Jun 11, 2026, 12:18 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

NCT02224781
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
Interventions
Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Ipilimumab, Multigated Acquisition Scan, Nivolumab, Quality-of-Life Assessment, Trametinib Dimethyl Sulfoxide
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
840
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 529 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 11, 2026, 12:18 AM EDT
Active, not recruiting Phase 2 Interventional

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

NCT06984328
View directory record Official record
Conditions
Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)
Interventions
Acasunlimab, Pembrolizumab
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 11, 2026, 12:18 AM EDT
Completed Phase 2 Interventional

A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide

NCT00135408
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Ipilimumab+ Placebo, Ipilimumab+ Budesonide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Jun 11, 2026, 12:18 AM EDT
Completed Phase 2 Interventional

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

NCT00005961
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
O6-benzylguanine, carmustine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
13
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Jun 11, 2026, 12:18 AM EDT
Completed Phase 1Phase 2 Interventional

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

NCT00429312
View directory record Official record
Conditions
Melanoma
Interventions
JX-594
Biological
Lead sponsor
Jennerex Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Los Angeles, California • Billings, Montana • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2015 · Synced Jun 11, 2026, 12:18 AM EDT
Completed Phase 1 Interventional Results available

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

NCT01024231
View directory record Official record
Conditions
Malignant Melanoma
Interventions
BMS-936558 (MDX1106-04), Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
4
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2021 · Synced Jun 11, 2026, 12:18 AM EDT
Terminated Phase 1 Interventional Results available

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02097225
View directory record Official record
Conditions
BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Solid Neoplasm
Interventions
Dabrafenib, Laboratory Biomarker Analysis, Onalespib, Pharmacological Study, Trametinib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Jun 11, 2026, 12:18 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma

NCT00412828
View directory record Official record
Conditions
Unresectable Stage III or Stage IV Melanoma
Interventions
CR011-vcMMAE
Drug
Lead sponsor
CuraGen Corporation
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
Santa Monica, California • New Haven, Connecticut • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Jun 11, 2026, 12:18 AM EDT